Skip to content

US · ZNTL · BIOTECHNOLOGY

Zentalis Pharmaceuticals, Inc. (ZNTL) intrinsic value and stock valuation

$1.36as of 2026-11-21 · Mkt cap 352.37M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zentalis Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ZNTL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ZNTL’s statements →

Zentalis Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 zentalis.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-137.06M
20182025
Free cash flow
-$-125.25M
20182025
Total equity
$216.2M-8.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$67.4M$0.00$0.00$0.00
Operating income-$-152.81M-$-191.19M-$-299.51M-$-227.29M-$-216.54M
Net income-$-137.06M-$-165.84M-$-292.19M-$-236.81M-$-158.72M
EPSd-$-1.91M-$-2.33M-$-4.47M-$-4.48M-$-3.72M
Operating cash flow-$-125.25M-$-170.86M-$-207.82M-$-163.75M-$-154.09M
Capital expenditure$0.00-$-220K-$-580K-$-2.55M-$-6.11M
Free cash flow-$-125.25M-$-171.08M-$-208.41M-$-166.3M-$-160.2M
Total assets$289M$430.3M$562M$553.5M$472M
Total debt$39.6M$42.7M$45.8M$47.3M$45.9M
Net debt$3.58M$8.75M$17.7M$4.26M-$-14.04M
Total equity$216.2M$337.2M$437.4M$434M$364.5M
Cash and short-term investments$245.9M$371.1M$482.9M$437.4M$340.1M
Income statement
20252024202320222021
Revenue$0.00$67.4M$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$67.4M$0.00$0.00$0.00
Research and development expenses$107.3M$167.8M$235.2M$172.7M$175.6M
Selling, general and administrative expenses$37.7M$87.1M$59.4M$54.6M$40.9M
Other expenses$7.8M$3.74M$4.95M$0.00$0.00
Operating expenses$152.8M$258.6M$299.5M$227.3M$216.5M
Cost and expenses$152.8M$258.6M$299.5M$227.3M$216.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$2.58M$0.00
Depreciation and amortization$740K$1.29M$1.39M$1.43M$540K
Ebitda-$-144.27M-$-186.17M-$-247.6M-$-233.58M-$-207.2M
Operating income-$-152.81M-$-191.19M-$-299.51M-$-227.29M-$-216.54M
Total other income/expenses, net$16.2M$25.5M$6.6M-$-10.29M$50.2M
Income before tax-$-136.62M-$-165.69M-$-292.91M-$-237.58M-$-166.39M
Income tax expense$440K$180K-$-600K-$-470K-$-300K
Net income-$-137.06M-$-165.84M-$-292.19M-$-236.81M-$-158.72M
Weighted average shares outstanding$71.9M$71.1M$65.4M$52.9M$42.7M
Weighted average diluted shares outstanding$71.9M$71.1M$65.4M$52.9M$42.7M
Balance sheet
20252024202320222021
Cash and short-term investments$245.9M$371.1M$482.9M$437.4M$340.1M
Net receivables$1.93M$5M$0.00$0.00$2.63M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$253.2M$386.1M$496.7M$451.9M$350.8M
Property, plant and equipment, net$29M$37.2M$41.7M$50.1M$52.8M
Goodwill and intangible assets$0.00$0.00$3.74M$3.74M$3.74M
Long-term investments$0.00$2.63M$2.68M$23.8M$40.1M
Total non-current assets$35.8M$44.3M$65.3M$101.5M$121.3M
Total assets$289M$430.3M$562M$553.5M$472M
Accounts payable$7.21M$7.44M$14.9M$11.3M$11.6M
Short-term debt$3.87M$3.07M$2.62M$2.16M$1.45M
Deferred revenue$0.00$0.00$280K$0.00$0.00
Total current liabilities$36.6M$52.7M$69.4M$56.7M$43.9M
Long-term debt$35.7M$39.6M$43.2M$45.2M$44.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$36.2M$40.4M$55.3M$62.8M$63.6M
Capital lease obligations$35.7M$39.6M$43.2M$47.3M$44.5M
Total liabilities$72.8M$93.2M$124.6M$119.4M$107.5M
Common stock$70K$70K$70K$60K$40K
Retained earnings-$-1.19B-$-1.05B-$-888.56M-$-596.37M-$-359.56M
Accumulated other comprehensive income (loss)$200K$560K$2.19M-$-1.35M-$-120K
Total equity$216.2M$337.2M$437.4M$434M$364.5M
Total investments$209.9M$339.8M$457.6M$418.1M$320.3M
Total debt$39.6M$42.7M$45.8M$47.3M$45.9M
Net debt$3.58M$8.75M$17.7M$4.26M-$-14.04M
Cash flow statement
20252024202320222021
Net income-$-137.06M-$-165.87M-$-292.19M-$-237.11M-$-166.09M
Depreciation and amortization$740K$1.29M$1.39M$1.43M$540K
Stock-based compensation$20.7M$67.3M$54.8M$46.8M$35.7M
Change in working capital-$-9.12M-$-16.54M$5.86M$13.3M$16.6M
Accounts receivable$5M-$-5M$0.00$0.00$410K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-17.32M-$-18.02M$10.9M$15.5M$14M
Net cash provided by operating activities-$-125.25M-$-170.86M-$-207.82M-$-163.75M-$-154.09M
Investments in property, plant and equipment$0.00-$-220K-$-580K-$-2.55M-$-6.11M
Acquisitions, net$0.00$70K$0.00$110K-$-14.32M
Net cash used for investing activities$131.6M$176.6M-$-44.46M-$-114.18M-$-18.11M
Common stock issued-$-4.28M$350K$237.3M$261M$179.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.28M$110K$237.3M$261M$178.5M
Net change in cash$2.09M$5.81M-$-14.98M-$-16.89M$6.31M
Cash at end of period$38.6M$36.5M$30.7M$45.7M$62.6M
Operating cash flow-$-125.25M-$-170.86M-$-207.82M-$-163.75M-$-154.09M
Capital expenditure$0.00-$-220K-$-580K-$-2.55M-$-6.11M
Free cash flow-$-125.25M-$-171.08M-$-208.41M-$-166.3M-$-160.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zentalis Pharmaceuticals, Inc.

        Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

        CEO
        Julia Marie Eastland
        Employees
        106
        Beta
        1.93

        Explore

        Frequently asked questions

        What is the intrinsic value of Zentalis Pharmaceuticals, Inc. (ZNTL)?

        InvestorsCraft does not currently publish an intrinsic value for ZNTL. How the IC value is calculated.

        Is ZNTL undervalued?

        InvestorsCraft does not publish an undervaluation signal for ZNTL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.